Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis
NCT06880770 · SHASTA-5 Phase 3Recruiting
- Lead sponsor
- Arrowhead Pharmaceuticals (Industry)
- Enrollment
- 288 (estimated)
- Start date
- 24 Apr 2025
- Primary completion
- Mar 2029 (estimated)
- Study completion
- 1 Jun 2029
- Last update posted
- 21 Sep 2026
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Randomized
- Intervention model
- Parallel
- Masking
- Quadruple
- Arms
- 2
Interventions
- Plozasiran Drug
- Placebo Drug
Conditions and primary outcome
- Severe Hypertriglyceridemia
Primary outcome
Time to First Occurrence of Positively Adjudicated AP Event (Event Occurring More Than 10 Days After First Dose of Study Drug) (Randomization up to end of Double Blind Treatment Period compared to placebo (Approximate Maximum 50 Months)])
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
No PubMed citation lists NCT06880770.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT06880770 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.